HNF1A rs1169300: What Your Genotype Means
The rs1169300 variant is a common missense change in the HNF1A gene leading to an amino acid substitution (p.Ile27Leu). Scientific research links this polymorphism to modest baseline variations in high-sensitivity C-reactive protein (hs-CRP) levels and slight shifts in metabolic markers related to glucose homeostasis. Because its individual effect size is small, having this variant represents an subtle biological influence rather than a medical diagnosis.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| AA | Carriers of the homozygous major genotype carry two copies of the ancestral allele, encoding isoleucine at position 27. This genotype is associated with baseline population-average HNF-1α transcriptional regulation of hepatic CRP and normal beta-cell metabolic signaling. | Informational |
| AC | Heterozygous individuals possess one copy of the common variant allele encoding leucine. Studies associate this genotype with subtle, statistically observed variations in baseline hs-CRP levels and minor metabolic variance, though overall clinical impact remains low. | Informational |
| CC | Homozygous carriers inherit two copies of the alternate allele encoding leucine at codon 27. While research links this genotype with modest statistical differences in circulating CRP and subtle variations in glucose homeostasis, it does not represent a monogenic diabetes mutation or independent medical pathology. | Informational |
What Is rs1169300 and Where Is It Located?
The single nucleotide polymorphism (SNP) designated rs1169300 is located within the coding sequence of the HNF1A gene on chromosome 12. At the DNA level, this alteration results in a codon change that substitutes the amino acid isoleucine with leucine at position 27 of the resulting peptide (p.Ile27Leu, also frequently indexed alongside rs1169288 in genetic literature due to strong linkage). Because isoleucine and leucine share similar nonpolar chemical properties, this missense substitution introduces a modest structural alteration rather than a catastrophic disruption of the protein. The variant is categorized as a common polymorphic trait variant rather than a high-penetrance mutation. In public databases like dbSNP, ClinVar, and gnomAD, it is cataloged as a common genetic variant evaluated primarily for its nuanced, continuous associations with metabolic and inflammatory biomarkers in large population cohorts.
The Biological Role of HNF1A
The HNF1A gene provides the genetic blueprint for hepatocyte nuclear factor 1-alpha (HNF-1α), a critical transcription factor expressed abundantly in the liver, pancreas, and kidneys. In pancreatic beta cells, HNF-1α governs the expression of numerous genes vital for glucose sensing and insulin secretion. In hepatocytes, it directly binds regulatory elements in promoter regions of hepatic proteins, including the gene encoding C-reactive protein (CRP). Rare, deleterious loss-of-function mutations in HNF1A cause maturity-onset diabetes of the young type 3 (MODY3), a monogenic form of diabetes characterized by deficient insulin release and markedly decreased serum CRP levels. While rs1169300 does not cause monogenic diabetes, understanding HNF-1α as an essential molecular bridge between liver biomarker synthesis and pancreatic function explains why subtle variations in this gene subtly alter systemic inflammation markers and glucose handling.
What the Research Associates with rs1169300
Genome-wide association studies (GWAS) and candidate gene analyses have repeatedly identified common polymorphisms in the HNF1A locus as significant genetic determinants of circulating high-sensitivity C-reactive protein (hs-CRP) levels. HNF-1α directly controls transcription at the CRP promoter; consequently, alleles of rs1169300 correlate with subtle, baseline adjustments in circulating CRP concentrations. In addition, epidemiological investigations into type 2 diabetes and metabolic homeostasis have analyzed the p.Ile27Leu substitution, showing that common HNF1A variants exert modest odds ratios on glucose regulation and diabetes susceptibility. However, the overall strength of evidence for rs1169300 having a major individual clinical consequence is limited. Unlike rare pathogenic MODY mutations, this common variant confers only minor statistical shifts across populations rather than causing overt clinical disease on its own.
How Common Is rs1169300 Across Populations?
Unlike the ultra-rare mutations that underlie monogenic diabetes, rs1169300 is highly prevalent throughout global human populations. Across major continental cohorts documented in the Genome Aggregation Database (gnomAD) and 1000 Genomes, the minor allele frequency typically ranges between 30% and 40%. This high degree of polymorphism demonstrates that carrying one or two copies of the variant allele is a normal evolutionary state rather than a pathological defect. The frequency distribution is relatively stable across diverse ancestral groups, including European, East Asian, and admixed American populations. Because tens of millions of healthy individuals worldwide carry the leucine-encoding allele without ever developing metabolic dysfunction, the presence of this variant cannot be interpreted in isolation as a sign of disease.
What You Can and Cannot Do with This Information
Learning your rs1169300 genotype provides educational context regarding normal biological variation, but it has important clinical limitations. This genetic marker cannot diagnose diabetes, predict cardiovascular events, or establish an individual's inflammatory status. Because the effect size on hs-CRP levels and glucose regulation is subtle, traditional clinical indicators—such as routine fasting plasma glucose, hemoglobin A1c (HbA1c), lipid panels, and standard inflammatory markers—remain the gold standards for evaluating cardiometabolic health. Genetic variants of limited effect should never prompt self-treatment or changes to prescribed medications. Anyone evaluating their diabetes risk or interpreting elevated lab values should consult a qualified physician or genetic counselor to discuss evidence-based dietary, lifestyle, and medical approaches.
How common is this variant?
The rs1169300 variant is common across diverse populations, displaying a minor allele frequency typically between 0.30 and 0.40 across major continental ancestries.
Frequently asked questions
Does having rs1169300 mean I have MODY3 diabetes?
No. MODY3 is caused by rare, high-impact pathogenic mutations in the HNF1A gene. In contrast, rs1169300 is an extremely common variant found in 30% to 40% of alleles worldwide that confers only very subtle population-level statistical differences in metabolic traits.
How does HNF1A affect C-reactive protein (CRP) levels?
HNF-1α serves as a direct transcription factor for the CRP gene in the liver, binding to its promoter region. Variants in HNF1A can slightly alter how strongly this promoter is activated, leading to minor variations in baseline circulating CRP concentration.
Can rs1169300 be used to predict my risk of type 2 diabetes?
On its own, rs1169300 has very limited predictive power for type 2 diabetes. Type 2 diabetes is a polygenic condition influenced by hundreds of genetic variants alongside lifestyle, age, and environmental factors.
Should I change my diet or medications based on my rs1169300 genotype?
No. Genetic test results for common trait variants should never guide independent changes to prescription medications or therapies. Standard medical care and monitoring by a licensed healthcare provider remain the proper method for managing blood sugar and inflammatory health.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1169300?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29